National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 9 of 1992)

Overview

The National Health Act 1953, enacted by the Commonwealth Parliament, was introduced to establish and maintain the National Health Service and to provide for other related matters. This legislation serves as the foundational framework for the regulation of health services and pharmaceutical benefits in Australia. One of the critical gaps it addresses is ensuring the efficient and equitable provision of health services and the regulation of pharmaceutical benefits to the Australian population. The Act empowers the government to manage and oversee the quality and accessibility of health services, including the Pharmaceutical Benefits Scheme (PBS). This legislative instrument, F2007B01082, is a specific declaration made under subsection 85(2AA) of the National Health Act 1953. The policy objective behind this declaration was to remove calcium glubionate from the list of drugs covered under Part VII of the Act, effective from 1 August 1992, after obtaining advice from the Pharmaceutical Benefits Advisory Committee.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 pertains to the regulation of pharmaceutical benefits within the Commonwealth of Australia. The Act applies to all individuals and entities that are involved in the provision, prescription, or administration of pharmaceutical benefits, as well as to the drugs themselves that are subject to the Pharmaceutical Benefits Scheme (PBS). This encompasses healthcare providers, pharmaceutical manufacturers, and patients who are eligible for PBS benefits. The scope of the Act extends nationally, applying uniformly across all states and territories of Australia, thereby ensuring a standardised approach to the regulation and subsidisation of medications. The exclusions under this specific Declaration include the cessation of calcium glubionate from being a drug to which Part VII of the National Health Act applies, effective from 1 August 1992. The application of the Act can be further defined and modified through subordinate instruments, which allow for the detailed administration and specific regulations concerning the PBS.

Key Provisions

The key operative sections of the Declaration under subsection 85 (2AA) of the National Health Act 1953 (sections 1 and 2) establish that, effective from 1 August 1992, the drug calcium glubionate will no longer be subject to Part VII of the Act. This means that the drug will no longer be eligible for the benefits and coverage provided under the Pharmaceutical Benefits Scheme (PBS). The declaration is made by Denise Mary Swift, Acting Assistant Secretary, Pharmaceutical Benefits Branch, and it follows the advice of the Pharmaceutical Benefits Advisory Committee. This directive alters the status of calcium glubionate from being a listed drug under the PBS to a non-listed drug, impacting its eligibility for subsidies and coverage. The Act imposes obligations on the entities and parties affected by this declaration, primarily ensuring that the changes are implemented from the specified effective date. This includes notifying relevant stakeholders, such as healthcare providers and patients, about the cessation of calcium glubionate's eligibility for PBS coverage. It also mandates that all records, systems, and processes are updated to reflect this change in the status of the drug. These obligations ensure that the transition is smooth and that there is no continued eligibility for benefits that are no longer applicable. Failure to comply with the provisions of this declaration may result in civil or criminal consequences. Although the specific offences and penalties are not detailed in the declaration itself, under the National Health Act 1953, breaches of provisions related to the PBS can attract penalties. For example, knowingly making a false statement or providing misleading information regarding a drug's eligibility for the PBS can lead to fines. The maximum penalties can vary depending on the nature and severity of the offence, but they may include substantial fines and, in severe cases, imprisonment. These consequences are intended to ensure compliance with the legislative requirements and maintain the integrity of the PBS.